• Century Therapeutics filed a new prospectus supplement for its at-the-market equity offering program for up to USD 150.0 million in common stock sales.
• TD Securities $(USA)$ is acting as sales agent under a sales agreement dated July 1, 2022.
• Common stock sold under the program totaled USD 18.38 million, leaving USD 131.62 million available for future sales.
• The company said its new shelf registration statement on Form S-3 became effective on January 9, 2026, replacing its prior shelf registration statement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-035256), on March 26, 2026, and is solely responsible for the information contained therein.